Two IGTP projects, financed with 1.6 million euros by the European Commission
At the beginning of December, the results of the evaluations of the projects presented within the Horizon Europe Framework Programme (HORIZON) of the European Commission were made public. The Germans Trias i Pujol Research Institute (IGTP) has obtained funding for two projects in the preclinical development of immunotherapies, with a total amount of 1,670,346 euros.
The projects that have passed the two phases and have been selected are:
Principal investigator: Eva Martínez Cáceres (Immunopathology)
Funding: 1.061.971 €
Objective: To develop and validate an advanced therapeutic medicinal product (ATMP) based on VitaminD3-modified tolerogenic dendritic cells (VitD3DC) for immunotherapy approaches. Through a multidisciplinary approach, IMMUTOL will harness the power of tolerogenic VitD3DC-based immunotherapy to develop a more potent and durable treatment for multiple sclerosis and/or other autoimmune inflammatory diseases with an unmet medical need.
Principal investigator: Pere Joan Cardona (Experimental Tuberculosis Unit)
Funding: 608.375 €
Objective: To develop innovative adjunctive immunotherapies against tuberculosis, taking advantage of a promising line of research and recent developments in the field. The project will combine current and new antibiotic regimens with novel immunotherapies, such as small molecules targeting host-pathogen interactions, including host-directed therapies and virulence inhibitors, immunomodulatory compounds, monoclonal antibodies, and therapeutic vaccines.
As Mireia Giménez Barcons, head of the International Projects Unit of the IGTP, points out "these results will have a great impact both at a scientific and social level, since they are based on the development of new immunotherapies for the treatment of diseases of great social impact such as tuberculosis and multiple sclerosis". She also remembers that "through totally innovative strategies and highly sophisticated techniques, the projects seek to boost the immune system to fight these diseases. These techniques can be a game changer in the fight against infectious and autoimmune diseases, and allow the research carried out at the IGTP to be at the forefront of research in these type of therapies."